摘要
Clinical management of advanced unresectable HCC has indelibly changed with the advent of immune checkpoint inhibitor(ICI)antibody therapy.The CheckMate-040 multi-cohort trial first demonstrated the effectiveness of an anti-PD1 antibody(nivolumab)in patients with clinically advanced HCC previously treated with sorafenib,reporting an approximately 20% overall objective response rate in such patients[1].Another anti-PD1 agent,pembrolizumab,demonstrated similar response rates in its phase 2 trial[2],and both agents subsequently received accelerated regulatory approval for second-line systemic treatment of HCC.
基金
supported by NIH R01CA262460。
